Patents by Inventor Kazuyoshi Sawada
Kazuyoshi Sawada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10494338Abstract: The present invention relates to a novel prostaglandin derivative having an alkynyl group on ?-chain, particularly, a novel prostaglandin derivative having a double bond at the 2-position and an alkynyl group on the ?-chain and a medicament containing the compound as an active ingredient. According to the present invention, a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof; wherein each symbol is as defined in the present specification, or a cyclodextrin clathrate compound thereof, and a medicament containing the compound as an active ingredient, particularly, a medicament for the prophylaxis or treatment of a blood flow disorder associated with spinal canal stenosis or chronic arterial occlusion, can be provided.Type: GrantFiled: May 9, 2017Date of Patent: December 3, 2019Assignees: AGC INC., NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Arata Yasuda, Yasushi Matsumura, Kazuyoshi Sawada, Hiroyoshi Nanba, Kazuki Taguchi
-
Publication number: 20190135743Abstract: The present invention relates to a novel prostaglandin derivative having an alkynyl group on ?-chain, particularly, a novel prostaglandin derivative having a double bond at the 2-position and an alkynyl group on the ?-chain and a medicament containing the compound as an active ingredient. According to the present invention, a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof; wherein each symbol is as defined in the present specification, or a cyclodextrin clathrate compound thereof, and a medicament containing the compound as an active ingredient, particularly, a medicament for the prophylaxis or treatment of a blood flow disorder associated with spinal canal stenosis or chronic arterial occlusion, can be provided.Type: ApplicationFiled: May 9, 2017Publication date: May 9, 2019Applicants: AGC INC., NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Arata YASUDA, Yasushi MATSUMURA, Kazuyoshi SAWADA, Hiroyoshi NANBA, Kazuki TAGUCHI
-
Patent number: 9365533Abstract: A novel coumarin derivative or a pharmaceutically acceptable salt thereof and also to provide a pharmaceutical agent containing such a compound as an active ingredient is provided. The coumarin derivative or a pharmaceutically acceptable salt thereof exhibits an excellent suppressive action to the destruction of cartilage and suppressive action to the proliferation of synovial cells in a pharmacological test where the release of sulfated glycosaminoglycans (sGAG) and the proliferation of synovial cells are used as indicators whereby it is very useful as an active ingredient of a pharmaceutical composition such as a preventive or therapeutic agent for arthropathy such as osteoarthritis or chronic rheumatoid arthritis.Type: GrantFiled: September 20, 2013Date of Patent: June 14, 2016Assignee: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Mitsuru Naiki, Tomoyuki Okada, Kazuyoshi Sawada, Takashi Ogino
-
Publication number: 20150297562Abstract: An object of the present invention is to provide an analgesic effective in a prophylactic or a therapy for various pain diseases. The present invention is to provide an analgesic containing at least one member selected from a trans-2-decenoic acid derivative represented by the formula (1) and a pharmaceutically acceptable salt thereof as an active ingredient: (In the formula, Y is —O—, —NR— or —S—, R is hydrogen atom, alkyl group, dialkylaminoalkyl group or the like and W is a substituent such as dialkylaminoalkyl group). The analgesic of the present invention containing the compound as an active ingredient is highly useful as a prophylactic or therapeutic agent for various pain diseases such as the pain caused by osteoarthritis (e.g., knee osteoarthritis and hip osteoarthritis).Type: ApplicationFiled: April 26, 2013Publication date: October 22, 2015Inventors: Munekazu IINUMA, Shoei FURUKAWA, Mitsuru NAIKI, Tomonori MATSUMOTO, Kazuyoshi SAWADA
-
Publication number: 20150232440Abstract: A novel coumarin derivative or a pharmaceutically acceptable salt thereof and also to provide a pharmaceutical agent containing such a compound as an active ingredient is provided. The coumarin derivative or a pharmaceutically acceptable salt thereof exhibits an excellent suppressive action to the destruction of cartilage and suppressive action to the proliferation of synovial cells in a pharmacological test where the release of sulfated glycosaminoglycans (sGAG) and the proliferation of synovial cells are used as indicators whereby it is very useful as an active ingredient of a pharmaceutical composition such as a preventive or therapeutic agent for arthropathy such as osteoarthritis or chronic rheumatoid arthritis.Type: ApplicationFiled: September 20, 2013Publication date: August 20, 2015Applicant: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Mitsuru Naiki, Tomoyuki Okada, Kazuyoshi Sawada, Takashi Ogino
-
Publication number: 20130296425Abstract: An object of the present invention is to provide a drug which is effective for prophylaxis or therapy of peripheral nerve disorder occurred as a side effect of the administration of anti-cancer agents. The present invention is to provide a drug containing an ester of C10 fatty acid as an active ingredient for prophylaxis or therapy of peripheral nerve disorder induced by administration of a drug containing at least one of anti-cancer agents. The drug of the present invention containing the compound as an active ingredient is highly useful as a drug for prophylaxis or therapy of peripheral nerve disorder induced by administration of anti-cancer agents.Type: ApplicationFiled: January 30, 2012Publication date: November 7, 2013Applicants: NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Munekazu Iinuma, Shoei Furukawa, Mitsuru Naiki, Tomoyuki Okada, Tomonori Matsumoto, Kazuyoshi Sawada
-
Publication number: 20130296426Abstract: An object of the present invention is to provide an analgesic effective in a prophylactic or a therapy for various pain diseases. The present invention is to provide an analgesic containing an ester of C10 fatty acid as an active ingredient. The analgesic of the present invention containing the compound as an active ingredient is highly useful as a prophylactic or therapeutic agent for various pain diseases such as the pain caused by osteoarthritis (e.g., knee osteoarthritis and hip osteoarthritis) or by demyelinating diseases such as multiple sclerosis or Guillain-Bareé syndrome.Type: ApplicationFiled: January 30, 2012Publication date: November 7, 2013Applicants: NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE, NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Munekazu Iinuma, Shoei Furukawa, Mitsuru Naiki, Tomoyuki Okada, Tomonori Matsumoto, Kazuyoshi Sawada
-
Publication number: 20060241162Abstract: (R)-(+)-5-hydroxy-1-methylhydantoin is an optically active substance having an excellent suppressive action of the progression of renal failure. At an administration to a model animal of renal failure, (R)-(+)-5-hydroxy-1-methylhydantoin significantly suppresses an increase of creatinine in blood as compared with the S-form and the racemate, and shows an excellent suppressive action to the progression of renal failure by improving creatinine clearance. Thus, (R)-(+)-5-hydroxy-1-methylhydantoin is useful as a highly-active agent for renal failure.Type: ApplicationFiled: April 20, 2005Publication date: October 26, 2006Inventors: Kaoru Okamoto, Akira Ishii, Nobuhisa Okukado, Hirohide Matsuura, Mitsuru Naiki, Kazuyoshi Sawada
-
Patent number: 6251929Abstract: A highly safe therapeutic agent for intractable vasculitis such as malignant rheumatoid arthritis contains a hydantoin derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof as an effective ingredient: wherein each of R1, and R2, which may be the same or different, represents hydrogen, an alkyl group or a cycloalkyl group; and each of X and Y, which may be the same or different, represents hydrogen, a hydroxyl group, an alkyl group or an alkoxy group, or X and Y together represent an oxo group. The hydantoin derivatives significantly suppress the generation of arthritis and arteritis (cutaneous ulcer and auricular infarcted necrosis) which are naturally developed in model animals (MRL/lpr), and further significantly elongate the survival rate of MRL/lpr mice. Consequently, the hydantoin derivatives, having low toxicity and little side effects are very useful as highly safe therapeutic agents for intractable vasculitis such as malignant rheumatoid arthritis.Type: GrantFiled: November 5, 1999Date of Patent: June 26, 2001Assignee: Nippon Zoki Pharmaceuticals Co., Ltd.Inventors: Mitsuru Naiki, Takumi Numazawa, Tomoyuki Okada, Kazuharu Ienaga, Kazuyoshi Sawada
-
Patent number: 4534664Abstract: An impact printing mechanism which contains a great number of printing types in a minimized spacing is disclosed. Types are arranged in rows of columns on a plurality of substantially planar type carrying elements which are accommodated in equally spaced parallel relationship in a removable casing. Selection of a type is attained by three dimensional movements including horizontal movements of the elements within and perpendicular to their planes and a vertical movement of an element within its plane.The type carrying elements are carried on a carrier while a print hammer is mounted on an independent carrier. The former carrier includes an outer section and an inner section mounted for movement on the outer section, and means for lifting a type carrying element is mounted on the outer section.Type: GrantFiled: April 22, 1983Date of Patent: August 13, 1985Assignee: Silver Seiko Ltd.Inventor: Kazuyoshi Sawada